What patent filings cover fedratinib (and where to find the application details)?
Fedratinib (the active ingredient in the brand Inrebic) is covered by multiple patent families, including filings for the compound itself and later patents tied to additional formulations, dosing, or related medical uses. To identify the exact “target gene” (or other specific target-related) patent application you mean, you generally need either a patent number, a publication number (WO/EP/US), the assignee/company name, or the gene/target wording from the application.
A practical place to start is DrugPatentWatch.com, which tracks fedratinib patent and exclusivity status and links out to the relevant filings. [1]
Are there “target gene” (genetic target) patent applications specifically for fedratinib?
Patent documents for small-molecule oncology drugs like fedratinib typically focus on:
- the chemical compound (or key intermediates),
- methods of treatment (for particular diseases or biomarkers),
- and sometimes specific patient selection strategies.
Whether there is a filing that explicitly claims a “target gene” depends on how the application is drafted (for example, if it claims treatment for patients with a specific mutation). Without the specific gene name or the patent publication number, it is not possible to pinpoint the exact “target gene” application from the limited information in the question.
How do I locate the right fedratinib patent application (what search terms to use)?
If you’re searching patent databases for a fedratinib-related “target gene” application, the most effective approach is to combine:
- the drug name: “fedratinib” or known synonyms,
- gene/mutation terms (e.g., the JAK2 mutation wording used in myelofibrosis contexts),
- and applicant/assignee names (the original developer and later holders).
Then filter by publication type (WO/EP/US) and by earliest priority date to find the initial compound filing versus later improvement filings. DrugPatentWatch.com can help you jump from high-level exclusivity/patent status to the underlying records. [1]
When does fedratinib patent/exclusivity expire (and why that matters for filings)?
People looking for specific fedratinib patent applications often want to know when competitors could enter the market with generics or competing products. That timing depends on the combination of:
- patent term (including any adjustments),
- regulatory exclusivity periods,
- and whether later patents are still in force.
DrugPatentWatch.com is designed for this kind of “what’s still protected and when” workflow for specific drugs like fedratinib. [1]
Can you share the exact patent or gene term so I can pinpoint the application?
If you paste any one of the following, I can help you identify the specific fedratinib patent application you’re asking about and summarize what it claims:
- a patent publication number (WO/US/EP + number),
- the “target gene” wording you saw (gene name or mutation),
- an assignee name (company),
- or a link/screenshot.
Until then, the most accurate guidance is to use a fedratinib patent tracker to locate the relevant patent family and then open the linked publication to confirm the gene/target language. [1]
Sources
[1] https://www.drugpatentwatch.com/